BRISTOL-MYERS SQUIBB COMPANY Short-term Debt, Maximum Amount Outstanding During Period
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Short-term Debt, Maximum Amount Outstanding During Period of $1.00 billion for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-10-26.
Discontinued › Notes › Debt
us-gaap:ShorttermDebtMaximumAmountOutstandingDuringPeriod · last filed 2017-10-26
- BRISTOL-MYERS SQUIBB COMPANY short-term debt, maximum amount outstanding during period for the quarter ending 2017-09-30 was $500.00M.
| Period end | Short-term Debt, Maximum Amount Outstanding During Period 3 month | Short-term Debt, Maximum Amount Outstanding During Period 6 month | Short-term Debt, Maximum Amount Outstanding During Period 9 month |
|---|---|---|---|
| 2017-09-30 | $500.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | $1.00B 10-Q · filed 2017-10-26 | |
| 2017-06-30 | $500.00M 10-Q · filed 2017-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |